ReShape Medical™, Inc. announced that it has initiated a U.S. Investigational Device Exemption (IDE) clinical study to assess the safety and effectiveness of its non-surgical, dual-balloon device for weight loss. The ReShape Balloons are designed to be a treatment for the millions who want support with weight loss, without the invasiveness of surgery. The ReShape device occupies existing space in the stomach to reduce its capacity for food. The balloons remain in place for six-months and are then removed. The first U.S…

See original here: 
ReShape Medical Announces Initiation Of U.S. Clinical Study For Weight Loss

You may also like:

• Society Of Toxicology Annual Meeting: Leading Toxicologists Highlight Advances To Safeguard Public Health
• Gynecologic Oncology Group Notifies CTI That Continuation Of GOG-212 Pivotal Trial Of OPAXIO Maintenance Therapy In Ovarian Cancer Is A Priority
• Artisan Pharma, Inc. Completes Enrollment In 750-patient Phase 2b Study Of ART-123 In Sepsis Patients With DIC
• Sizing Up Nanotechnology: How Nanosized Particles May Affect Skin Care Products
• Key Caldolor(R) Orthopedic Data To Be Presented At American Academy Of Orthopaedic Surgeons’ Annual Meeting
• Stupak Renews Abortion Threats In Health Reform
• TOPICA Announces Positive Phase 2 Clinical Results For Luliconazole, A Potent Topical Antifungal
• Lantheus Medical Imaging, Inc. Initiates Phase 1 Study Evaluating Safety And Dosimetry Of Novel Heart Failure Imaging Agent
• Nektar Announces Dosing Of First Patients In Phase 1 Clinical Study Of NKTR-102 In Combination With 5-Fluorouracil/Leucovorin
• Dendreon Announces Presentation Of PROVENGE Data At The American Society Of Clinical Oncology Annual Meeting